Transvenous onyx embolization for dural arteriovenous fistula with concomitant transvenous balloon protection of the venous sinus.

The purpose of this study was to evaluate the efficacy and safety technical transvenous embolization Onyx for dural arteriovenous fistula (DAVFs) with transvenous balloon protection as venous sinuses when transarterial route fails or not feasible.Between September 2010 and December 2016, thirty -enam patients with DAVFs transvenous lead intracranial balloon-assisted embolization Onyx.

Efficacy technical, treatment-related complications, and angiographic results and clinical review of our prospectively maintained DAVF database.According with Cognard classification, 11 patients presented with clinical symptoms of type I Cognard; 11 cases with this type IIa Cognard; 10 cases with Cognard types IIb and 4 cases with Cognard types IIa + b. DAVFs complete angiographic occlusion of the latest follow-up (median 18 months after transvenous embolization) was achieved in 28 patients (77.8%), a near-complete occlusion angiography with minimal residual fistula in 5 patients (13.9%) and reduction significant flow of DAVF in 2 patients (5.6%) and residual fistula for further treatment in 1 (2.8%) patients. The number of clinical cure or remission of symptoms pre-treatment was achieved in 31 patients (31/36, 86.1%; 26 and 5 cases respectively).

Affected venous sinus was preserved in 28 patients, accidentally clogged in 7 patients and gradually clogged in 1 patient. No terms of persistent complication directly or shortly after treatment.Transvenous Onyx embolization of dural arteriovenous fistula with transvenous protection from venous sinus balloon combination is safe and effective in achieving a high degree of occlusion, embolization related complications is low and satisfactory clinical results.

TRIPC Polyclonal Antibody

ABP60762-003ml 0.03ml
EUR 158.00
  • Immunogen information: Synthesized peptide derived from part region of human TRIPC protein at amino acid sequence of 950-1030
  • Applications tips:
Description: A polyclonal antibody for detection of TRIPC from Human, Mouse, Rat. This TRIPC antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human TRIPC protein at amino acid sequence of 950-1030

TRIPC Polyclonal Antibody

ABP60762-01ml 0.1ml
EUR 289.00
  • Immunogen information: Synthesized peptide derived from part region of human TRIPC protein at amino acid sequence of 950-1030
  • Applications tips:
Description: A polyclonal antibody for detection of TRIPC from Human, Mouse, Rat. This TRIPC antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human TRIPC protein at amino acid sequence of 950-1030

TRIPC Polyclonal Antibody

ABP60762-02ml 0.2ml
EUR 414.00
  • Immunogen information: Synthesized peptide derived from part region of human TRIPC protein at amino acid sequence of 950-1030
  • Applications tips:
Description: A polyclonal antibody for detection of TRIPC from Human, Mouse, Rat. This TRIPC antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human TRIPC protein at amino acid sequence of 950-1030

Anti-TRIPC antibody

STJ191207 200 ┬Ál
EUR 197.00
Description: Unconjugated Rabbit polyclonal to TRIPC
Scroll to Top